Heron Therapeutics is trading at $0.37, up 11.28%, with no fresh company-specific catalyst identified for the October 7 move.
- The broader market and biotech sector are lower, so neither explains the share-price rise.
- Available reporting mentions earlier quarterly results and a September licensing agreement, but links neither to the move. The company’s latest listed release was August 10.